Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
Fulgent Genetics Community
NasdaqGM:FLGT Community
2
Narratives
written by author
0
Comments
on narratives written by author
11
Fair Values set
on narratives written by author
Create a narrative
Community Investing Ideas
Fulgent Genetics
Popular
Undervalued
Overvalued
Fulgent Genetics
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Declining Sequencing Costs And Precision Medicine Will Expand Markets
Key Takeaways Rapid execution in sales force expansion, managed care, and international launches positions Fulgent for market share gains and multi-year revenue diversification. Proprietary drug delivery and genomic sequencing advances enable accelerated entry into new therapeutic areas, margin improvement, and industry-leading growth potential.
View narrative
US$30.00
FV
32.1% undervalued
intrinsic discount
10.84%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Fulgent Genetics
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Enhanced Whole Genome Sequencing Will Open New Global Markets
Key Takeaways Broadened clinical endorsements, new service launches, and international certifications strengthen market position, drive revenue growth, and diversify global reach. Operational efficiencies and expanded managed care contracts boost volume growth, enhance gross margins, and establish a sustainable foundation for future profitability.
View narrative
US$25.33
FV
19.6% undervalued
intrinsic discount
10.45%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
Updated
narrative
Your Valuation for
FLGT
FLGT
Fulgent Genetics
Your Fair Value
US$
Current Price
US$20.36
23.0% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-163m
925m
2015
2018
2021
2024
2025
2027
2030
Revenue US$489.1m
Earnings US$36.5m
Advanced
Set Fair Value